AI Analysis | Feedback

Here are 1-3 brief analogies for Pliant Therapeutics:

• The Vertex Pharmaceuticals of fibrosis.

• An early-stage Regeneron, but focused on treatments for fibrosis.

AI Analysis | Feedback

• PLN-74809: An oral small-molecule dual selective inhibitor targeting avß6 and avß1 integrins, currently in three Phase 2a trials for fibrosis and related diseases.
• PLN-1474: A small-molecule selective inhibitor of avß1, which has completed Phase 1 clinical trials for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH).
• Oncology Program: A preclinical integrin-based program under development for the treatment of cancer.
• Muscular Dystrophies Program: A preclinical program developing an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for muscular dystrophies, including Duchenne muscular dystrophy.

AI Analysis | Feedback

Pliant Therapeutics, Inc. (PLRX) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for fibrosis and related diseases. As described, their lead product candidates are in Phase 1 and Phase 2a clinical trials, and they also have preclinical programs.

At this stage of development, Pliant Therapeutics is primarily engaged in research and development and conducting clinical trials. The company does not yet have commercialized products available for sale. Therefore, Pliant Therapeutics does not have major customers in the traditional sense of companies or individuals purchasing its products or services.

AI Analysis | Feedback

AI Analysis | Feedback

Bernard Coulie, M.D., Ph.D. President and Chief Executive Officer

Bernard Coulie co-founded ActoGeniX, a biotech company, where he served as CEO, Chief Medical Officer, and Co-Founder. ActoGeniX was acquired by Intrexon Corporation in February 2015. Prior to ActoGeniX, Dr. Coulie held various positions in drug discovery and clinical development at Johnson & Johnson Pharmaceutical Research and Development Europe, where he managed a portfolio of products in GI, metabolic diseases, and inflammation/immunology. He joined Pliant Therapeutics as CEO in 2015, after the company was established in 2016, and Pliant Therapeutics has raised significant venture and private equity capital under his leadership. He is also Board Chairman of Flindr Therapeutics, a privately-held precision oncology company, a Director of Septerna, a privately-held biotechnology company, and Independent Chairman of Dualyx, a privately-held biotechnology company.

Keith Cummings, M.D., MBA Chief Financial Officer

Keith Cummings has served as Chief Financial Officer of Pliant Therapeutics since December 2018. He manages the company's capital structure. His background includes an M.D. from Duke University and an MBA from Duke Fuqua.

Éric Lefebvre, M.D. Chief Medical Officer

Éric Lefebvre oversees the clinical pipeline at Pliant Therapeutics. He has been noted as a Chief Medical Officer at the company.

Minnie Kuo Chief Operating Officer

Minnie Kuo was appointed Chief Operating Officer of Pliant Therapeutics on December 10, 2025. She initially joined the company in September 2023 as Chief Development Officer. Ms. Kuo brings over 20 years of multinational clinical development experience. Before joining Pliant, she held roles of increasing responsibility at Vir Biotechnology, including Senior Vice President of Translational and Clinical Development Operations. She also held senior clinical operations positions at Nektar Therapeutics and Gilead Sciences, and global project management and clinical study management roles at Roche/Genentech, ICON, and PharmaNet.

Delphine Imbert, Ph.D. Chief Technical Officer

Delphine Imbert serves as the Chief Technical Officer at Pliant Therapeutics.

AI Analysis | Feedback

1. Clinical Trial Failure and Regulatory Approval Risk: As a clinical-stage biopharmaceutical company, Pliant Therapeutics' success hinges entirely on the ability of its product candidates, including PLN-74809 (in Phase 2a trials) and PLN-1474 (completed Phase 1), to successfully complete clinical trials and obtain regulatory approval. There is a high risk that these candidates may fail to demonstrate sufficient efficacy or safety in ongoing or future trials, encounter unforeseen side effects, or fail to meet the stringent requirements of regulatory bodies, thereby preventing their approval and commercialization.

AI Analysis | Feedback

null

AI Analysis | Feedback

Addressable Markets for Pliant Therapeutics' Main Products

Pliant Therapeutics (PLRX) focuses on developing therapies for fibrotic diseases, with two of its main product candidates being PLN-74809 and PLN-1474.

PLN-74809 (Idiopathic Pulmonary Fibrosis and Primary Sclerosing Cholangitis)

PLN-74809 is an oral small-molecule dual selective inhibitor in Phase 2a trials for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).

• Idiopathic Pulmonary Fibrosis (IPF): The global market for IPF was valued at approximately USD 3.3 billion in 2023 across the 7 major markets (US, EU4, UK, Japan). Other global estimates include USD 3.76 billion in 2023, projected to reach USD 6.80 billion by 2032, and USD 4.54 billion in 2024, projected to reach USD 9.23 billion by 2033. North America is a dominant region in the IPF market.
• Primary Sclerosing Cholangitis (PSC): The global primary sclerosing cholangitis market was estimated at approximately USD 800 million in 2023 and is projected to grow to USD 1.2 billion by 2032. Other estimates suggest the global market was valued at USD 337 million in 2024 and is expected to reach USD 661 million by 2032. North America leads the PSC market.

PLN-1474 (Liver Fibrosis Associated with Nonalcoholic Steatohepatitis - NASH)

PLN-1474, a small-molecule selective inhibitor, completed Phase 1 clinical trials for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis (NASH). This program is partnered with Novartis.

• NASH with Liver Fibrosis: The NASH market size across the 7 major markets was approximately USD 2.11 billion in 2023 and is projected to increase during the forecast period of 2024–2034. In 2023, the U.S. market for NASH was approximately USD 1.52 billion. The broader global liver fibrosis treatment market was valued at USD 17.51 billion in 2024 and is projected to reach USD 51.16 billion by 2033. North America dominates the liver fibrosis market, holding approximately 40% of the market share.

AI Analysis | Feedback

Pliant Therapeutics (NASDAQ: PLRX), a clinical-stage biopharmaceutical company, is expected to drive future revenue growth over the next 2-3 years through a combination of milestone payments from existing collaborations, potential new partnerships for its advancing pipeline, and the progression of its lead clinical candidates.

Here are the key drivers:

1. Milestone Payments and Royalties from Novartis Collaboration for PLN-1474: Pliant Therapeutics has a strategic collaboration with Novartis for its PLN-1474 program, a selective inhibitor of αvß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Pliant completed Phase 1 development, and Novartis is now responsible for all future development, manufacturing, and commercialization. Pliant is eligible to receive up to $416 million in milestone payments upon achievement of development, regulatory, and commercialization milestones, in addition to tiered royalties on future sales. The significant revenue projected by analysts for 2027 ($235 million) and 2028 (over $1.1 billion) is likely to be substantially driven by these milestone payments as PLN-1474 progresses through clinical trials under Novartis's stewardship.

2. Advancement of the Oncology Program (PLN-101095) Leading to Potential Partnerships/Licensing Deals: Pliant is increasingly focusing on its oncology pipeline, specifically PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins for solid tumors. Recent positive Phase 1 data in immune checkpoint inhibitor-refractory solid tumors, including observed complete and partial responses, has led to an accelerated development plan with a Phase 1b indication expansion trial. Successful continued clinical development of this promising oncology asset could attract new strategic partnerships or licensing agreements, generating upfront payments and development milestones within the next 2-3 years.

3. Progression of PLN-74809 (Bexotegrast) for Primary Sclerosing Cholangitis (PSC) through Later-Stage Clinical Milestones: Although Pliant discontinued its BEACON-IPF Phase 2b/3 trial for Idiopathic Pulmonary Fibrosis (IPF), its lead product candidate, PLN-74809 (bexotegrast), continues in development for Primary Sclerosing Cholangitis (PSC). PLN-74809 has received Fast Track designation and Orphan Drug designation from the FDA for PSC, which may expedite its development and review process. While commercialization may extend beyond the 2-3 year timeframe, achieving significant clinical milestones in later-stage trials for PSC could trigger additional payments from potential future partners or enhance the company's valuation, contributing to revenue growth.

4. Formation of New Strategic Partnerships/Collaborations for Other Pipeline Programs: Pliant Therapeutics has a broader integrin-based platform and additional preclinical programs, including PLN-101325, a monoclonal antibody agonist targeting muscular dystrophies like Duchenne muscular dystrophy, which has received regulatory clearance for a Phase 1 study. Successful early-stage development of these or other undisclosed integrin-based programs could lead to new collaborations, similar to the Novartis agreement, providing upfront payments, research funding, and potential milestone payments as these candidates advance through clinical development.

AI Analysis | Feedback

Share Repurchases

No share repurchase programs were identified for Pliant Therapeutics over the last 3-5 years. However, in March 2026, Pliant Therapeutics extended its Stockholder Rights Agreement's expiration from March 11, 2026, to March 11, 2027. This extension aims to deter any entity from gaining control through open market share accumulation without paying a control premium or allowing sufficient time for the board to evaluate options.

Share Issuance

• In January 2023, Pliant Therapeutics priced an upsized underwritten public offering of 8,333,334 shares of its common stock at $30.00 per share, with expected gross proceeds of approximately $250.0 million.
• The company commenced an underwritten public offering of $150.0 million of its common stock in July 2022, along with a 30-day option for underwriters to purchase up to an additional $22.5 million. The net proceeds were designated for ongoing and future preclinical and clinical programs, platform development, working capital, operating expenses, and capital expenditures.
• Pliant Therapeutics completed its Initial Public Offering (IPO) in 2020, generating $184 million in gross proceeds.

Inbound Investments

• Pliant and Novartis entered into a Collaboration and License Agreement in October 2019 for PLN-1474 and up to three integrin research targets, which included an $80 million initial payment to Pliant (a $50 million upfront fee and $30 million in equity investment commitments from Novartis).
• In June 2022, Pliant received a $4 million milestone payment and research funding from Novartis for the advancement of a fibrosis-directed integrin target under their collaboration agreement.
• Pliant Therapeutics secured a loan facility agreement with Oxford Finance LLC in May 2022, providing up to $100 million in non-dilutive financing to support the clinical development of PLN-74809, which extended its expected cash runway to mid-2024.

Capital Expenditures

• Pliant Therapeutics reported capital expenditures of -$583,000 over the last 12 months.
• In Q3 2025, the company's capital expenditures were $0, which was a 100% decrease from the prior quarter.
• The net proceeds from the July 2022 public offering were intended, in part, to fund capital expenditures.